keyword
MENU ▼
Read by QxMD icon Read
search

primary peritoneal cancer

keyword
https://www.readbyqxmd.com/read/28334032/does-hysteroscopy-worsen-prognosis-in-women-with-type-ii-endometrial-carcinoma
#1
Jiao Chen, Leslie H Clark, Wei-Min Kong, Zhen Yan, Chao Han, Hui Zhao, Ting-Ting Liu, Tong-Qing Zhang, Dan Song, Si-Meng Jiao, Chunxiao Zhou
BACKGROUND: Prior studies evaluating the impact of hysteroscopy on outcomes in endometrial cancer have predominantly evaluated type I tumors. We sought to evaluate whether hysteroscopy worsens prognosis in type II endometrial cancer. METHODS: A retrospective cohort analysis of 140 patients from two institutions with type II endometrial cancer was performed. Women who underwent either diagnostic hysteroscopy (HSC) or dilation and curettage (D&C) for cancer diagnosis from June 2001 until June 2010 were included...
2017: PloS One
https://www.readbyqxmd.com/read/28333841/audit-of-ca125-follow-up-after-first-line-therapy-for-ovarian-cancer
#2
Daniel Krell, Fran Said Battistino, Sarah Benafif, Lochani Ganegoda, Marcia Hall, Gordon J S Rustin
AIMS: The Medical Research Council OVO5/EORTC 55955 trial showed that patients in remission after first-line therapy for ovarian cancer did not benefit from routine measurement of CA125 during follow-up. Since the presentation of these results, we have counseled patients about the options for follow-up and provided them with an information leaflet about the trial results and the symptoms that should prompt an early appointment and CA125 measurement. We present an audit of practice after the presentation of those results...
March 23, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28332034/patterns-of-initial-recurrence-in-gastric-adenocarcinoma-in-the-era-of-preoperative-therapy
#3
Naruhiko Ikoma, Hsiang-Chun Chen, Xuemei Wang, Mariela Blum, Jeannelyn S Estrella, Keith Fournier, Paul Mansfield, Jaffer Ajani, Brian D Badgwell
BACKGROUND: We sought to determine the sites of recurrence and identify predicting factors for recurrence and survival in patients who underwent gastrectomy for adenocarcinoma at an institution where preoperative therapy is commonly used for advanced gastric cancer. METHODS: We collected clinicopathologic data and sites of recurrence from a prospectively maintained database of patients who underwent potentially curative resection of gastric or gastroesophageal adenocarcinoma at our institution in 1995-2014, and we assessed associations between these characteristics and recurrence patterns and survival...
March 22, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28330549/-hyperthermic-intraperitoneal-chemotherapy-at-the-primary-gastrointestinal-cancer-operation
#4
Thea Helene Degett, Hans-Christian Pommergaard, Ismail Gögenur
Up to 20% of the patients who undergo radical surgery for colorectal cancer experience recurrence. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery have shown to be effective treatment of peritoneal carcinomatosis. HIPEC administered at the primary operation in high-risk patients may also be effective in preventing peritoneal carcinomatosis and improve survival in patients with advanced gastrointestinal cancer.
March 20, 2017: Ugeskrift for Laeger
https://www.readbyqxmd.com/read/28327944/a-phase-2-randomized-double-blind-placebo-%C3%A2-controlled-study-of-chemo-immunotherapy-combination-using-motolimod-with-pegylated-liposomal-doxorubicin-in-recurrent-or-persistent-ovarian-cancer-a-gynecologic-oncology-group-partners-study
#5
B J Monk, M F Brady, C Aghajanian, H A Lankes, T Rizack, J Leach, J M Fowler, R Higgins, P Hanjani, M Morgan, R Edwards, W Bradley, T Kolevska, P Foukas, E Swisher, K S Anderson, R Gottardo, J K Bryan, M Newkirk, K L Manjarrez, R S Mannel, R M Hershberg, G Coukos
Background: A phase 2, randomized, placebo-controlled trial was conducted in women with recurrent epithelial ovarian carcinoma to evaluate the efficacy and safety of motolimod-a Toll-like receptor 8 (TLR8) agonist that stimulates robust innate immune responses-combined with pegylated liposomal doxorubicin (PLD), a chemotherapeutic that induces immunogenic cell death. Patients and methods: Women with ovarian, fallopian tube, or primary peritoneal carcinoma were randomized 1 : 1 to receive PLD in combination with blinded motolimod or placebo...
February 21, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28323210/the-protective-activity-of-mesothelial-cells-against-peritoneal-growth-of-gastrointestinal-tumors-the-role-of-soluble-icam-1
#6
Justyna Mikuła-Pietrasik, Paweł Uruski, Małgorzata Kucińska, Andrzej Tykarski, Krzysztof Książek
In this project we examined how the presence of human peritoneal mesothelial cells (HPMCs) modifies (supports or inhibits) colorectal and pancreatic cancer cell progression in mice peritoneal cavity. Experiments were performed using primary, omentum-derived HPMCs, commercially available colorectal (SW-480) and pancreatic (PSN-1) cancer cells, and immunocompromised SCID mice. Tumor growth within the peritoneal cavity was monitored using bioluminescence. Adhesion of the cancer cells to HPMCs was examined using a fluorescence-based method, while the incidence of apoptosis was quantified using flow cytometry...
March 17, 2017: International Journal of Biochemistry & Cell Biology
https://www.readbyqxmd.com/read/28320418/ovarian-cancer-stem-cells-still-an-elusive-entity
#7
REVIEW
Michela Lupia, Ugo Cavallaro
The cancer stem cell (CSC) model proposes that tumor development and progression are fueled and sustained by undifferentiated cancer cells, endowed with self-renewal and tumor-initiating capacity. Ovarian carcinoma, based on its biological features and clinical evolution, appears as a prototypical example of CSC-driven disease. Indeed, ovarian cancer stem cells (OCSC) would account not only for the primary tumor growth, the peritoneal spread and the relapse, but also for the development of chemoresistance, thus having profound implication for the treatment of this deadly disease...
March 20, 2017: Molecular Cancer
https://www.readbyqxmd.com/read/28315929/adnexal-masses-associated-with-peritoneal-involvement-diagnosis-with-ct-and-mri
#8
REVIEW
Audrey Ognong-Boulemo, Anthony Dohan, Christine Hoeffel, Agatha Stanek, François Golfier, Olivier Glehen, Pierre-Jean Valette, Pascal Rousset
Given the unique intra-peritoneal anatomic location of the adnexa, tubo-ovarian diseases can commonly spread into the peritoneal cavity. Peritoneal seeding may occur in a spectrum of adnexal conditions including infectious diseases, endometriosis, and benign or malignant primary or secondary ovarian tumors. CT is usually the imaging modality on which the concomitant involvement of the peritoneum and the ovary is depicted. The first diagnosis to be considered by the radiologist is generally peritoneal carcinomatosis from ovarian cancer but other conditions cited above have also to be borne in mind and may be suggested on the basis of careful assessment of CT findings or on further MR findings...
March 18, 2017: Abdominal Radiology
https://www.readbyqxmd.com/read/28303528/human-mass-balance-study-and-metabolite-profiling-of-14-c-niraparib-a-novel-poly-adp-ribose-polymerase-parp-1-and-parp-2-inhibitor-in-patients-with-advanced-cancer
#9
Lotte van Andel, Z Zhang, S Lu, V Kansra, S Agarwal, L Hughes, M M Tibben, A Gebretensae, L Lucas, M J X Hillebrand, H Rosing, J H M Schellens, J H Beijnen
Niraparib is an investigational oral, once daily, selective poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor. In the pivotal Phase 3 NOVA/ENGOT/OV16 study, niraparib met its primary endpoint of improving progression-free survival (PFS) for adult patients with recurrent, platinum sensitive, ovarian, fallopian tube, or primary peritoneal cancer in complete or partial response to platinum-based chemotherapy. Significant improvements in PFS were seen in all patient cohorts regardless of biomarker status...
March 16, 2017: Investigational New Drugs
https://www.readbyqxmd.com/read/28288188/evaluations-of-primary-lesions-by-endoscopy-clearly-distinguishes-prognosis-in-patients-with-gastric-cancer-who-receive-chemotherapy
#10
Tomomitsu Tahara, Tomoyuki Shibata, Masaaki Okubo, Tomohiko Kawamura, Noriyuki Horiguchi, Dai Yoshida, Takamitsu Ishizuka, Mitsuo Nagasaka, Yoshihito Nakagawa, Naoki Ohmiya
BACKGROUND: Chemotherapy may improve outcomes in gastric cancer (GC), especially for the patients with advanced stage. To explore useful predictive factor for GC performing chemotherapy, we compared the tumor responses assessed using computed tomography (CT) with endoscopy based criteria. METHODS: 192 GC patients performing chemotherapy were retrospectively studied. CT based response assessment was performed after 2 courses of treatment. Endoscopic evaluation according to The Japanese classification of gastric carcinoma was also performed at same period...
2017: PloS One
https://www.readbyqxmd.com/read/28288057/mesorectal-excision-with-or-without-lateral-lymph-node-dissection-for-clinical-stage-ii-iii-lower-rectal-cancer-jcog0212-a-multicenter-randomized-controlled-noninferiority-trial
#11
Shin Fujita, Junki Mizusawa, Yukihide Kanemitsu, Masaaki Ito, Yusuke Kinugasa, Koji Komori, Masayuki Ohue, Mitsuyoshi Ota, Yoshihiro Akazai, Manabu Shiozawa, Takashi Yamaguchi, Hiroyuki Bandou, Kenji Katsumata, Kohei Murata, Yoshihito Akagi, Nobuhiro Takiguchi, Yoshihisa Saida, Kenichi Nakamura, Haruhiko Fukuda, Takayuki Akasu, Yoshihiro Moriya
OBJECTIVE: The aim of the study was to confirm the noninferiority of mesorectal excision (ME) alone to ME with lateral lymph node dissection (LLND) in terms of efficacy. BACKGROUND: Lateral pelvic lymph node metastasis is occasionally found in clinical stage II or III lower rectal cancer, and ME with LLND is the standard procedure in Japan. ME alone, however, is the international standard surgical procedure for rectal cancer. METHODS: Eligibility criteria included histologically proven rectal cancer at clinical stage II/III; main lesion located in the rectum, with the lower margin below the peritoneal reflection; no lateral pelvic lymph node enlargement; Peformance Status of 0 or 1; and age 20 to 75 years...
March 10, 2017: Annals of Surgery
https://www.readbyqxmd.com/read/28279466/current-progress-in-the-adjuvant-treatment-of-gastric-cancer
#12
REVIEW
David H Ilson
Staging of locally advanced gastric cancer includes imaging with computed tomography scan and laparoscopic assessment to rule out peritoneal disease or positive peritoneal washings. Preoperative and postoperative chemotherapy improves survival compared with surgery alone. After primary D2 resection, adjuvant chemotherapy with a fluorinated pyrimidine with or without a platinum agent improves survival. Inclusion of postoperative radiation therapy appears required in combination with chemotherapy in patients with less than a D1-D2 resection...
April 2017: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/28266500/absence-of-pd-l1-on-tumor-cells-is-associated-with-reduced-mhc-i-expression-and-pd-l1-expression-increases-in-recurrent-serous-ovarian-cancer
#13
Stefanie Aust, Sophie Felix, Katharina Auer, Anna Bachmayr-Heyda, Lukas Kenner, Sabine Dekan, Samuel M Meier, Christopher Gerner, Christoph Grimm, Dietmar Pils
Immune-evasion and immune checkpoints are promising new therapeutic targets for several cancer entities. In ovarian cancer, the clinical role of programmed cell death receptor ligand 1 (PD-L1) expression as mechanism to escape immune recognition has not been clarified yet. We analyzed PD-L1 expression of primary ovarian and peritoneal tumor tissues together with several other parameters (whole transcriptomes of isolated tumor cells, local and systemic immune cells, systemic cytokines and metabolites) and compared PD-L1 expression between primary tumor and tumor recurrences...
March 7, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28265738/radiolabeled-pertuzumab-for-imaging-of-human-epidermal-growth-factor-receptor-2-expression-in-ovarian-cancer
#14
Dawei Jiang, Hyung-Jun Im, Haiyan Sun, Hector F Valdovinos, Christopher G England, Emily B Ehlerding, Robert J Nickles, Dong Soo Lee, Steve Y Cho, Peng Huang, Weibo Cai
PURPOSE: Human epidermal growth factor receptor 2 (HER2) is over-expressed in over 30% of ovarian cancer cases, playing an essential role in tumorigenesis and metastasis. Non-invasive imaging of HER2 is of great interest for physicians as a mean to better detect and monitor the progression of ovarian cancer. In this study, HER2 was assessed as a biomarker for ovarian cancer imaging using (64)Cu-labeled pertuzumab for immunoPET imaging. METHODS: HER2 expression and binding were examined in three ovarian cancer cell lines (SKOV3, OVCAR3, Caov3) using in vitro techniques, including western blot and saturation binding assays...
March 6, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28263384/mesothelium-expression-of-vascular-cell-adhesion-molecule-1-vcam-1-is-associated-with-an-unfavorable-prognosis-in-epithelial-ovarian-cancer-eoc
#15
Jennifer M Scalici, Sanja Arapovic, Erin J Saks, Kristen A Atkins, Gina Petroni, Linda R Duska, Jill K Slack-Davis
BACKGROUND: Mesothelium vascular cell adhesion molecule-1 (VCAM-1) expression in the metastatic epithelial ovarian cancer (EOC) microenvironment is induced by tumor and mediates tumor cell invasion. VCAM-1 imaging suggests expression during treatment is an indicator of platinum resistance. Here, we assess the potential prognostic significance of mesothelium VCAM-1 expression and prospectively evaluate whether soluble VCAM-1 (sVCAM-1) is a surrogate for mesothelium expression. METHODS: A retrospective review of EOC patients was performed to evaluate outcomes with mesothelium VCAM-1 expression determined by immunohistochemistry of peritoneum or omentum specimens...
May 15, 2017: Cancer
https://www.readbyqxmd.com/read/28262692/mir-139-5p-as-a-novel-serum-biomarker-for-recurrence-and-metastasis-in-colorectal-cancer
#16
Jinsei Miyoshi, Shusuke Toden, Kazuhiro Yoshida, Yuji Toiyama, Steven R Alberts, Masato Kusunoki, Frank A Sinicrope, Ajay Goel
Approximately 30-50% of colorectal cancer (CRC) patients who undergo curative resection subsequently experience tumor recurrence or metastasis. Although microRNAs (miRNAs) are a class of small noncoding RNAs frequently deregulated in various human malignancies, it remains unknown if these can help predict recurrence and metastasis in CRC patients. MiRNAs were initially screened using miRNA-microarray and miRNA-seq datasets with or without recurrence. Candidate miRNAs were then tested in two independent cohorts of 111 stage II/III and 139 stage I-III CRC patients, as well as serum samples and matched primary and metastatic liver tissues...
March 6, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28261765/complicated-colorectal-cancer-in-nonagenarian-patients-is-it-better-not-to-perform-anastomosis-in-emergency
#17
Belinda De Simone, Federico Coccolini, Luca Ansaloni, Antonio Tarasconi, Gianluca Baiocchi, Nereo Vettoretto, Peggy Joly, Marianne Ferron, Alessandro Pozzo, Lionel Charre, Salomone Di Saverio, Josephine Andrea Napoli, Ferdinando Agresta, Massimo Sartelli, Fausto Catena
BACKGROUND: Colorectal cancer (CRC) is predominantly a disease of elderly people. Cancer in nonagenarian patients presents an ethical dilemma for surgeons and oncologists, and management of this group of patients in emergency for complicated CRC is debated. Presently described is retrospective study reporting experience of 6 departments of emergency surgery with management of nonagenarian patients sent to emergency surgery for CRC complications. METHODS: Data concerning patients aged over 90 years hospitalized from January 2011 to June 2015 in 6 departments of emergency surgery for complicated CRC were retrospectively analyzed...
January 2017: Ulusal Travma Ve Acil Cerrahi Dergisi, Turkish Journal of Trauma & Emergency Surgery: TJTES
https://www.readbyqxmd.com/read/28247413/mesothelial-to-mesenchymal-transition-as-a-possible-therapeutic-target-in-peritoneal-metastasis-of-ovarian-cancer
#18
Angela Rynne-Vidal, Chi Lam Au-Yeung, José A Jiménez-Heffernan, María Luisa Pérez-Lozano, Lucía Cremades-Jimeno, Carmen Bárcena, Ignacio Cristóbal-García, Concepción Fernández-Chacón, Tsz Lun Yeung, Samuel C Mok, Pilar Sandoval, Manuel López-Cabrera
Peritoneal dissemination is the primary metastatic route of ovarian cancer (OvCa), often accompanied by accumulation of ascitic fluid. The peritoneal cavity is lined by mesothelial cells (MCs), which can convert into carcinoma-associated fibroblasts (CAFs) through mesothelial-to-mesenchymal transition (MMT). Here, we demonstrate that MCs isolated from ascitic fluid (AFMCs) of OvCa patients with peritoneal implants also undergo MMT and promote subcutaneous tumour growth in mice. RNA sequencing of AFMCs revealed that MMT-related pathways-including TGF-β signalling-are differentially regulated, and a gene signature was verified in peritoneal implants from OvCa patients...
March 1, 2017: Journal of Pathology
https://www.readbyqxmd.com/read/28247011/population-pharmacokinetics-of-abt-767-in-brca1-or-brca2-mutation-carriers-with-advanced-solid-tumors-or-in-subjects-with-high-grade-serous-ovarian-primary-peritoneal-or-fallopian-tube-cancer
#19
Rajendar K Mittapalli, Silpa Nuthalapati, Stacie Peacock Shepherd, Hao Xiong
PURPOSE: The objective of the manuscript is to describe the development of a population pharmacokinetic model for ABT-767, a potent and orally bioavailable inhibitor of poly (ADP-ribose) polymerase enzyme, and to evaluate the potential influence of patient demographics and baseline covariates on the pharmacokinetics of ABT-767. METHODS: A total of 1809 plasma ABT-767 concentrations from 90 subjects were used for population pharmacokinetic modeling. Covariates screened for influence on pharmacokinetic parameters were body weight, lean body weight, body surface area, albumin, creatinine clearance, serum creatinine, liver function tests, and age...
February 28, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28238354/optimal-primary-management-of-bulky-stage-iiic-ovarian-fallopian-tube-and-peritoneal-carcinoma-are-the-only-options-complete-gross-resection-at-primary-debulking-surgery-or-neoadjuvant-chemotherapy
#20
Vasileios D Sioulas, Maria B Schiavone, David Kadouri, Oliver Zivanovic, Kara Long Roche, Roisin O'Cearbhaill, Nadeem R Abu-Rustum, Douglas A Levine, Yukio Sonoda, Ginger J Gardner, Mario M Leitao, Dennis S Chi
OBJECTIVE: To explore the impact of primary debulking surgery (PDS) to minimal but gross residual disease (RD) in women with bulky stage IIIC ovarian, fallopian tube, or primary peritoneal cancer. METHODS: We retrospectively reviewed all patients with the aforementioned diagnosis who underwent PDS at our institution from 01/2001-12/2010. Those with disease of non-epithelial histology or borderline tumors were excluded. Clinicopathologic data were abstracted, and appropriate statistical tests were used...
February 18, 2017: Gynecologic Oncology
keyword
keyword
63801
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"